Analyst: New study confirms that Eli Lilly's tirzepatide is a good product

Eli Lilly has published strong results for its study of the diabetes treatment tirzepatide, which took up the last piece of the puzzle needed for an FDA application, Sydbank analyst Søren Løntoft Hansen says.

Photo: Sydbank/PR

On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs